<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534065</url>
  </required_header>
  <id_info>
    <org_study_id>BARD-CP-001</org_study_id>
    <nct_id>NCT01534065</nct_id>
  </id_info>
  <brief_title>Barricaid EU Post Market Study for Primary Lumbar Disc Herniation</brief_title>
  <official_title>A Multi-center, Post Marketing Surveillance Study to Monitor the Safety and Performance of the Barricaid® ARD in the Treatment of Back and Radicular Pain Caused by Primary Lumbar Disc Herniation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intrinsic Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intrinsic Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this multi-center post marketing surveillance study is to monitor the safety
      and performance of the Barricaid® ARD when used to surgically reconstruct the anulus of the
      L1 - S1 spinal disc.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient function as measured on Oswestry Disability Index (ODI)</measure>
    <time_frame>24 months</time_frame>
    <description>15-point reduction in ODI at 24-month visit relative to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disc height maintenance as measured from standing x-rays</measure>
    <time_frame>24 months</time_frame>
    <description>75% maintenance at 2 years relative to pre-op, measured by independent radiologist, (reference: Yorimitsu, et al, Spine 2001)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically symptomatic recurrent herniation at the index level, confirmed by imaging</measure>
    <time_frame>24 months</time_frame>
    <description>Performed at 24 months by the Investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Migration of the bone anchor posteriorly into the epidural space</measure>
    <time_frame>24 months</time_frame>
    <description>Radiographic imaging taken to ensure no migration of the device. Assessment made by the Investigator and Radiographic Core lab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Removal or revision of the implant</measure>
    <time_frame>24 months</time_frame>
    <description>Any removal or revision of the implant will be measured as a safety outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Supplemental fixation applied at the treated level</measure>
    <time_frame>24 months</time_frame>
    <description>Any supplemental fixation applied at the treated level will be tracked.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Back Pain on Visual Analog Scale (VAS)</measure>
    <time_frame>24 months</time_frame>
    <description>Back pain on VAS will be tracked.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg Pain on Visual Analog Scale (VAS)</measure>
    <time_frame>24 months</time_frame>
    <description>Leg pain assessment will be tracked. Patient reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life on SF36</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life on SF36 will be tracked. Patient reported outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of neurological symptoms on clinical examination, relative to baseline</measure>
    <time_frame>24 months</time_frame>
    <description>Patient will have the following examinations: straight leg raising, deep tendon reflexes, forward bend, motor strength examination (hip flexors, knee extensors, tibialis, long toe extensors), and sensory (light touch, pin prick, or vibration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AE's</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency of AE's reported throughout the study will be tracked and analyzed at the 24 month visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Lumbar Disc Herniation</condition>
  <arm_group>
    <arm_group_label>Barricaid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CE Marked Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Barricaid</intervention_name>
    <description>Implanted intra-operatively during discectomy</description>
    <arm_group_label>Barricaid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 75 years old (male or female).

          2. Patients with posterior or posterolateral disc herniations at one or two levels
             between L1 and S1 with radiographic confirmation of neural compression using CT and/or
             MRI.

          3. At least six (6) weeks of failed, conservative treatment prior to surgery, including
             physical therapy, use of anti-inflammatory medications at maximum specified dosage
             and/or administration of epidural/facet injections.;

          4. Minimum posterior disc height of 3mm at the index level(s).

          5. Lower back pain and/or sciatica with or without spinal claudication.

          6. Oswestry Questionnaire score of at least 40/100 at baseline.

          7. VAS leg pain of at least 40/100 at baseline.

        Exclusion Criteria:

          1. Spondylolisthesis Grade II or higher

          2. Subject requires uni or bilateral facetectomy to treat leg/back pain

          3. Subject has back or non-radicular leg pain of unknown etiology.

          4. Prior fusion (with or without instrumentation), motion preservation, facetectomy or
             IDET surgery at the index lumbar vertebral level

          5. Subject's requiring a spine DEXA (i.e., patients with SCORE of ≥ 6) with a T Score
             less than -2.0 at the index level.

          6. Subject has clinically compromised vertebral bodies at the index level(s) due to any
             traumatic, neoplastic, metabolic, or infectious pathology.

          7. Subject has sustained pathologic fractures of the vertebra or multiple fractures of
             the vertebra or hip.

          8. Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).

          9. Any metabolic disease bone disease that has not been stabilized for at least three
             months (e.g., Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or
             parathyroid gland disorder, etc.).

         10. Subject has an active infection either systemic or local.

         11. Subject has cauda equine syndrome or neurogenic bowel/bladder dysfunction.

         12. Subject has severe arterial insufficiency of the legs (Screening on physical
             examination= patients with diminution or absence of dorsalis pedis or posterior
             tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is
             required with vascular plethysmography. If the absolute arterial pressure is below
             50mm of Hg at the calf or ankle level, then the patient is to be excluded) or other
             peripheral vascular disease).

         13. Subject has significant peripheral neuropathy, patient defined as a patient with Type
             I or Type II diabetes or similar systemic metabolic condition causing decreased
             sensation in a stocking-like or non-radicular and non-dermatomal distribution in the
             lower extremities.

         14. Subject has insulin-dependent diabetes mellitus.

         15. Subject is morbidly obese (defined as a body mass index &gt;40, or weighs more than 100
             lbs over ideal body weight).

         16. Subject has been diagnosed with active hepatitis, AIDS, or HIV.

         17. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.

         18. Subject has a known allergy to titanium, polyethylene or polyester materials.

         19. Subject is pregnant or interested in becoming pregnant in the next three (3) years.

         20. Subject has active tuberculosis or has had tuberculosis in the past three (3) years.

         21. Subject has a history of active malignancy: A patient with a history of any invasive
             malignancy (except non-melanoma skin cancer), unless he/she has been treated with
             curative intent and there have been no signs or symptoms of the malignancy for at
             least two (2) years.

         22. Subject is immunologically suppressed, received steroids &gt;1 month over the past year.

         23. Currently taking anticoagulants, other than aspirin, unless the patient can be taken
             off the anticoagulant for surgery

         24. Subject has a current chemical/alcohol dependency or significant psychosocial
             disturbance.

         25. Subject has a life expectancy of less than three (3) years.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Lequin MB, Barth M, Thomė C, Bouma GJ. Primary limited lumbar discectomy with an annulus closure device: one-year clinical and radiographic results from a prospective, multi-center study. Korean J Spine. 2012 Dec;9(4):340-7. doi: 10.14245/kjs.2012.9.4.340. Epub 2012 Dec 31.</citation>
    <PMID>25983843</PMID>
  </results_reference>
  <results_reference>
    <citation>Bouma GJ, Barth M, Ledic D, Vilendecic M. The high-risk discectomy patient: prevention of reherniation in patients with large anular defects using an anular closure device. Eur Spine J. 2013 May;22(5):1030-6. doi: 10.1007/s00586-013-2656-1. Epub 2013 Feb 3.</citation>
    <PMID>23377540</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hernia</keyword>
  <keyword>Intervertebral Disk Displacement</keyword>
  <keyword>Pathological Conditions, Anatomical</keyword>
  <keyword>Spinal Diseases</keyword>
  <keyword>Bone Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

